Skip to main content
The William Harvey Research Institute - Faculty of Medicine and Dentistry
  1. WHRI
  2. People
  3. Academic staff
  4. Items

Dr Manikandan Subramanian

Manikandan

Reader in Cardiovascular Inflammation and Deputy Director of Research

Centre: Biochemical Pharmacology

Email: m.subramanian@qmul.ac.uk
X: @Mani_CVD

Profile

ORCID iD: 0000-0002-2608-3890

Mani obtained his medical degree and clinical training from Kilpauk Medical College, India. He then pursued PhD in Immunology at the National Institute of Immunology followed by post-doctoral research at Columbia University Medical Center, New York, USA. Subsequently, Mani worked as an Associate Research Scientist in the Department of Medicine at Columbia University Medical Center before establishing his independent research laboratory in India as a Senior Scientist and Assistant Professor at the Institute of Genomics and Integrative Biology, New Delhi. His research was supported by grants from the Department of Biotechnology, Department of Science and Technology, Council of Scientific and Industrial Research, and an Intermediate Fellowship from the Wellcome Trust-DBT India Alliance. He joined the William Harvey Research Institute as a Senior Lecturer in Cardiovascular Inflammation in June 2020 to establish a research group focusing on understanding the mechanistic basis of impaired inflammation resolution response during dyslipidemia and to developing novel therapeutic strategies.

Research

Group members

Dr Stefan Russo (Postdoctoral Research Associate); Dr Umesh Dhawan (Postdoctoral Research Associate); Aarushi Singhal (PhD student); Purbasha Bhattachary (PhD student - External) 

Summary

Cardiovascular diseases including myocardial infarction, stroke, and heart failure is the leading cause of death worldwide. One of the fundamental pathological process underlying these clinical conditions is the formation of an atherosclerotic plaque, which is characterized by the build-up of fat and fat-filled cells in the vascular wall. A subset of these atherosclerotic plaques progress to an advanced stage and display heightened inflammation, large areas of necrosis, and thin fibrous cap, pathological features that make them vulnerable to plaque rupture and adverse clinical outcomes. 

Our laboratory uses a combination of cell biology tools, animal models of obesity and atherosclerosis, as well patient samples for understanding the mechanistic basis of advanced atherosclerotic plaque progression with the ultimate goal of identifying therapeutic targets and drugs that would prevent rupture of atherosclerotic plaques via plaque stabilization.

Major research themes

  1. Understanding the immune and inflammatory mechanisms that lead to advanced atherosclerosis progression and associated complications.
  2. Understanding the mechanistic basis of accelerated atherosclerosis progression in people with obesity.
  3. Development of therapeutic strategies to promote inflammation resolution and stabilization of atherosclerotic plaques.

Publications

  • Singhal A, Russo S, Dhawan UK et al. (2025). TRIB3 Links Endoplasmic Reticulum Stress to Impaired Efferocytosis in Atherosclerosis. nameOfConference


  • Dhawan UK, Vartak T, Englert H et al. (2025). Macrophage DNases Limit Neutrophil Extracellular Trap–Mediated Defective Efferocytosis in Atherosclerosis. nameOfConference


  • Shetty S, Subramanian M (2025). Neutrophil Extracellular Traps (NETs) as drivers of atherosclerosis: Pathogenic mechanisms and therapeutic opportunities. nameOfConference


  • Dhawan U, Singhal A, Englert H et al. (2025). Macrophage-secreted dnase prevents neutrophil extracellular trap mediated impairment of efferocytosis in atherosclerosis. nameOfConference


    QMRO: qmroHref
  • Singhal A, Dhawan U, Bhutia K et al. (2024). Lipid-induced ATF4 signalling impairs macrophage efferocytosis and promotes atherosclerotic plaque necrosis. nameOfConference


  • Bhattacharya P, Dhawan UK, Hussain MT et al. (2023). Efferocytes release extracellular vesicles to resolve inflammation and tissue injury via prosaposin-GPR37 signaling. nameOfConference


  • Perretti M, Subramanian M (2023). Resolution pharmacology − A fresh approach to the clinical management of human inflammatory diseases. nameOfConference


  • Dhawan UK, Margraf A, Lech M et al. (2022). Hypercholesterolemia promotes autoantibody production and a lupus‐like pathology via decreased DNase‐mediated clearance of DNA. nameOfConference


  • Bhattacharya P, Kanagasooriyan R, Subramanian M (2022). Tackling inflammation in atherosclerosis: Are we there yet and what lies beyond?. nameOfConference


    QMRO: qmroHref
  • Manickam V, Dhawan UK, Singh D et al. (publicationYear). Pomegranate Peel Extract Decreases Plaque Necrosis and Advanced Atherosclerosis Progression in Apoe -/- Mice. nameOfConference


View profile publication page

Sponsors

Collaborators

Internal

External

  • Professor Catherine Godson, University College Dublin, Ireland
  • Professor Shantanu Sengupta, CSIR-Institute of Genomics and Integrative Biology, India

Disclosures

No disclosures.

Back to top